組み合わせ単一ドメイン抗体ライブラリーの段階的ファージ選択による高特異的化学的誘起タンパク質二量体化システムの作成

Executive Industry Relevance

Engineering chemically induced dimerization (CID) systems enables precise, ligand-dependent control of protein interactions for biosensor development in drug discovery and pathway modulation. The COMBINES-CID method provides a scalable, library-driven approach to generate high-specificity dimerization pairs without requiring specialized equipment, supporting rapid prototyping of biosensors for intracellular metabolite, signaling molecule, or drug monitoring. This accelerates target validation and mechanistic de-risking by enabling real-time, spatiotemporal interrogation of biological processes in live cells.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through ligand-dependent protein dimerization, allowing functional validation of targets in native cellular contexts.
• Operational Value: Uses a single diverse nanobody library to select binders for multiple ligands, reducing library development time and cost across target classes.
• Predictive Value: Generates biosensors with ligand-dependent dimerization readouts that correlate with target engagement, supporting early go/no-go decisions based on biological activity.

Screening & Assay Development

• Scientific Value: Produces anchor and dimerization binders that form heterodimers only in the presence of a specific ligand, enabling homogeneous, wash-free detection formats.
• Operational Value: Leverages phage display and ELISA-based validation compatible with standard lab infrastructure, facilitating technology transfer across discovery teams.
• Assay Readiness: Generates binders suitable for fusion into genetically encoded biosensors for real-time metabolite or drug tracking in live-cell assays.

Translational & Preclinical Research

• Translational Continuity: Supports development of biosensors for in vivo monitoring of drugs, metabolites, or signaling molecules in yeast or mammalian cells, enabling pharmacokinetic and pharmacodynamic profiling.
• Mechanistic De-risking: Allows dissection of pathway dynamics via chemically controlled dimerization, reducing ambiguity in target mechanism and downstream effect prediction.
• Predictive Confidence: Provides quantitative, ligand-dependent dimerization data (e.g., via size-exclusion chromatography) to inform biomarker suitability and assay translation.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead optimization, enabling biosensor integration at multiple stages to monitor target modulation and pathway activity with high specificity.

• Discovery Biology: Supports hypothesis testing by allowing chemically controlled dimerization to probe target function and pathway relationships in live systems.
• Screening: Generates binder pairs compatible with homogeneous assays for screening modulator effects on dimerization in response to ligand exposure.
• Analytics: Enables quantitative readouts via ELISA, BLI, or size-exclusion chromatography to assess binding affinity, selectivity, and ligand-dependent complex formation.
• Translational Research: Facilitates advancement to preclinical models by encoding biosensors in mammalian systems for real-time target engagement monitoring.
• Enterprise Reuse: The core selection strategy can be reapplied across ligands and projects, establishing a reusable platform for biosensor generation.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by enabling ligand-dependent control of protein interactions, improving confidence in target-disease relationships.
• Operational Value: Uses standard phage display and bench-top validation (ELISA, BLI), minimizing need for specialized instrumentation and lowering barrier to adoption.
• Strategic Value: Improves decision efficiency by providing early, biologically relevant biosensor readouts that reduce reliance on surrogate markers.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on validated, ligand-dependent biosensor performance in cellular contexts.

Implementation Considerations

• Requires expertise in phage display, protein engineering, and biosensor design for library screening and binder characterization.
• Depends on access to biotinylated ligands and streptavidin-coated beads for selection steps, with validation via BLI or ELISA.
• Necessitates standardization of binder expression and purification formats for consistent dimerization assessment across teams.
• Adaptation to intracellular environments may require optimization of linker design, expression levels, and compartment targeting in yeast or mammalian cells.
• Practical limitations include dependence on ligand accessibility and binding kinetics, which may affect biosensor sensitivity and dynamic range in complex cellular milieus.

Biopharma FAQs